Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUR-928 in mild to moderate plaque psoriasis
NCT03837743Phase 2Completed
- Sponsor
- DURECT Corporation
- Start
- Feb 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in plaque psoriasis comparing DUR-928 Topical Solution with Vehicle Topical Solution (2 arms). Primary endpoint: Investigator's Global Assessment at 8 weeks. Started Feb 2019; status: completed.
02
Drugs
larsucosterol
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03837743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03837743.